Skip to Main Content
Chapter 27

++

INTRODUCTION

++

Epidemiology

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Epidemiology
Incidence: 24,050 (male: 13,500; female: 10,550. Durie-Salmon Stage at presentation
Estimated new cases for 2014 in the United States) Stage I 6%
7.5 per 100,000 males, 4.8 per 100,000 females Stage II 21%
Deaths: Estimated 11,090 in 2014 (male: 6,110; female: 4,980) Stage III 73%
Median age: 69 years
Male to female ratio: 1.4:1

Durie BGM, Salmon SE. Cancer 1975;36:842–854

Siegel R et al. CA Cancer J Clin 2014;64:9–29

Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)

++

Pathology

Monoclonal gammopathy of uncertain significance (MGUS)

  • Stable serum M-protein level <3 g/dL and bone marrow clonal plasma cells <10%

  • Urine Bence Jones protein absent or minimal

  • No related organ/tissue impairment (ROTI)

  • No evidence of other B-lymphoproliferative disorders

  • Progression to multiple myeloma (MM) in ~1% per year (median 10 years)

Smoldering (asymptomatic) myeloma

  • M-protein in serum ≥30 g/L and/or bone marrow clonal plasma cells ≥10%

  • No ROTI or symptoms

Active (symptomatic) myeloma

  • Requires one or more of the following (CRAB criteria):

  • Calcium elevation (>11.5 mg/dL [>2.88 mmol/L])

  • Renal insufficiency (creatinine >2 mg/dL [>177 μmol/L])

  • Anemia (hemoglobin <10 g/dL or 2 g less than normal)

  • Bone disease (lytic or osteopenic)

Extramedullary plasmacytoma

  • Extramedullary tumor of clonal plasma cells

  • Normal bone marrow

  • Normal skeletal survey

  • M-protein absent or disappears from blood/urine after excision or irradiation of solitary lesion

  • Absence of ROTI

  • Progression to MM in ~15%

Solitary plasmacytoma of bone

  • Three to 5% of plasma cell dyscrasias

  • Isolated bone tumor consisting of monoclonal plasma cells

  • Normal bone marrow

  • M-protein absent or disappears from blood/urine after excision or irradiation of solitary lesion

  • Absence of other myeloma ROTI

  • Multiple or recurrent in up to 5% of patients

  • Progression to MM in ~50%

Plasma cell leukemia

  • Five percent of newly presenting MM patients

  • Peripheral blood absolute plasma cell count ≥2000/mm3

  • More than 20% plasma cells in differential count of peripheral blood leukocytes

++

Work-up

All patients

  1. H&P

  2. CBC with differential; serum electrolytes, BUN, creatinine, calcium and albumin, LDH

  3. Quantitative immunoglobulins, serum protein electrophoresis, and immunofixation

  4. Twenty-four–hour urine protein electrophoresis, immunofixation, and Bence Jones quantitation

  5. Serum free light-chain assay

  6. Skeletal survey

  7. Unilateral bone marrow aspirate and biopsy with flow and immunohistochemistry

  8. Bone marrow cytogenetics and interphase FISH

  9. Albumin and β2-microglobulin (see staging system)

Selected patients

  1. MRI of the spine (evaluate for solitary plasmacytoma of bone or suspected cord compression)

  2. FDG-PET/CT scan in selected patients to evaluate for increased uptake

  3. Tissue biopsy (evaluate for solitary plasmacytoma)

  4. Serum viscosity (if M-protein level is markedly elevated or symptoms of hyperviscosity are present)

  5. Additional tests (prognostic markers): plasma cell labeling index, C-reactive protein, and LDH

++

Staging

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
Staging

Durie-Salmon Staging System

...
  Stage I Stage II

Stage III

Myeloma cell mass Low Intermediate High
Hemoglobin >10 g/dL 8.5–10 g/dL <8.5 g/dL
Serum calcium ≤12 mg/dL (≤3 mmol/L) Fitting neither stage I nor stage II >12 mg/dL (>3 mmol/L)
Skeletal survey Normal Advanced lytic bone lesions
Serum M-protein levels: IgG <5 g/dL 5–7 g/dL

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.